

TiPs: A database of therapeutic targets in pathogens and associated tools

Rosalba Lepore¹, Anna Tramontano^{1,2,3,*} and Allegra Via^{1,*}

¹Department of Physics, ²Center for Life Nano Science @Sapienza, Istituto Italiano di Tecnologia and ³Istituto Pasteur, Fondazione Cenci Bolognetti, Sapienza University, 00185 Rome, Italy

Associate Editor: Prof. Alfonso Valencia

ABSTRACT

Motivation: The need for new drugs and new targets is particularly compelling in an era that is witnessing an alarming increase of drug resistance in human pathogens. The identification of new targets of known drugs is a promising approach, which has proven successful in several cases. Here, we describe a database that includes information on 5153 putative drug-target pairs for 150 human pathogens derived from available drug-target crystallographic complexes.

Availability and implementation: The TiPs Database is freely available at <http://biocomputing.it/tips>

Contact: anna.tramontano@uniroma1.it, allegra.via@uniroma1.it

1 INTRODUCTION

Novel mechanisms to escape therapy are constantly emerging among human pathogen populations and this clearly urges the development, on one hand, of new drugs for the treatment of the diseases and, on the other hand, of rapid and effective methods to help expanding the landscape of available treatment options (Hopkins, et al., 2011). In this context, computational studies are called upon to help identify novel therapeutic targets and characterise their interactions, and indeed a number of such efforts are described in the literature (Aguero, et al., 2008; Kinnings, et al., 2010; Lepore, et al., 2011; Orti, et al., 2009). However, these are mostly devoted to the analysis of single targets or specific tropical disease pathogens. The TiPs Database has been developed with the aim of facilitating the identification of new therapeutic targets in more than 150 organisms responsible for human infections. We performed a large-scale analysis to systematically identify candidate targets in the proteomes of such organisms. The rationale of our approach is based on the intrinsic polypharmacological behaviour of compounds targeting homologous proteins (Paolini, et al., 2006). We considered all drug-target pairs for which the three-dimensional (3D) structure of the complex is experimentally known and used the sequence of the target to identify its homologues in human pathogens. The evolutionary conservation of such homologues and their 3D structures (available or predicted) were used to verify whether the original drug was in principle able to bind them as it does the original target. To this aim, stringent filters were applied to ensure that predicted binding sites and their interactions with the drug are as accurate as possible. Pathogen proteins predicted with

high confidence to be therapeutic targets and the putative drugs interacting with them were collected and annotated in TiPs.

2 METHODS

More than 400 human pathogen species were obtained from “The Approved List of Biological Agents” provided by the Advisory Committee on Dangerous Pathogens. In order to unambiguously assign an identifier (ID) to human pathogens, the names of the organisms were mapped onto the NCBI Taxonomy Database records (<http://www.ncbi.nlm.nih.gov/Taxonomy/>).

Drug compounds and information on their molecular targets were obtained from DrugBank (<http://www.drugbank.ca>). The SMILE IDs of drugs annotated either as “inhibitor”, “agonist” or “antagonist” were used to associate them with ligands present in the PDB structure entries (Berman, et al., 2012). Only identical compounds were considered (Tanimoto coefficient = 1). A total of 308 distinct drugs were observed in complex with at least one PDB structure. About 40% of these (119/308) occur in complex with their actual pharmaceutical target. These were used as starting points to predict potential drug targets in pathogens. The search for homologues in pathogens was performed using BLAST+ (Camacho, et al., 2009) with default parameters against the nr database (<ftp://ftp.ncbi.nlm.nih.gov/blast/db/>). We only retained highly reliable hits, i.e. those showing at least 40% sequence identity to the original target and $e\text{-value} < 10^{-6}$. Pathogen taxonomic IDs were retrieved by matching the gi numbers of BLAST hits to the NCBI Taxonomy database.

For each known drug-target complex, we defined the binding site as the subset of target residues having at least one atom within 3.5 Å distance from any atom of the drug. The drug binding site residues in the predicted pathogen sequences were retrieved through a multiple sequence alignment (MSA) of the original target sequence with its homologues generated with T-coffee (Taly, et al., 2011). The number and type of aligned residues were used to classify the binding site local conservation, both in terms of sequence coverage (percentage of binding site residues in the original target that could be aligned to the pathogen sequence) and identity (percentage of identical residues among the aligned binding site residues). Coverage and identity percentages were calculated separately for each pathogen sequence in the alignment. Only pathogen proteins showing at least 80% coverage in their binding sites were further considered (4215 in total). Among these 4215 reliable putative targets, only 41 have a solved structure in the PDB. Homology modelling

*To whom correspondence should be addressed.

